Background Primary pulmonary hypertension is a progressive disease for which no treatment
has been shown in a prospective, randomized trial to improve survival. Methods We …

Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure ≥25 mm Hg
at rest, measured during right heart catheterization. There is still insufficient evidence to add …

Background: Pulmonary hypertension is a progressive and often fatal complication of the
scleroderma spectrum of disease for which no treatment has been proven effective in a …

The aim of a clinical classification of pulmonary hypertension (PH) is to group together different
manifestations of disease sharing similarities in pathophysiologic mechanisms, clinical …

In 1998, during the Second World Symposium on Pulmonary Hypertension (PH) held in
Evian, France, a clinical classification of PH was proposed. The aim of the Evian classification …

Background Pulmonary hypertension is characterized by an increase in vascular tone or an
abnormal proliferation of muscle cells in the walls of small pulmonary arteries. Endothelin-1 …

Background Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase
2 trial to be beneficial in the treatment of pulmonary arterial hypertension. Methods In this …

Objective: To explore the role of endothelin-1, a potent endothelial-derived vasoconstrictor
peptide, in pulmonary hypertension, by measuring its concentration in arterial and venous …

Sitaxsentan may benefit patients with pulmonary arterial hypertension by blocking the
vasoconstrictor effects of endothelin-A while maintaining the vasodilator/clearance functions of …

Objectives : We sought to determine the optimal dose of the selective endothelin A (ET A )
receptor antagonist sitaxsentan for the treatment of pulmonary arterial hypertension (PAH); for …